vs
Side-by-side financial comparison of APPFOLIO INC (APPF) and Axsome Therapeutics, Inc. (AXSM). Click either name above to swap in a different company.
APPFOLIO INC is the larger business by last-quarter revenue ($262.2M vs $196.0M, roughly 1.3× Axsome Therapeutics, Inc.). APPFOLIO INC runs the higher net margin — 16.2% vs -14.6%, a 30.8% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 20.4%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 15.3%).
AppFolio, Inc. is an American company founded in 2006 that offers software-as-a-service (SaaS) applications and services to the real estate industry.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
APPF vs AXSM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $262.2M | $196.0M |
| Net Profit | $42.4M | $-28.6M |
| Gross Margin | — | — |
| Operating Margin | 19.4% | -13.8% |
| Net Margin | 16.2% | -14.6% |
| Revenue YoY | 20.4% | 65.0% |
| Net Profit YoY | 35.2% | 61.9% |
| EPS (diluted) | $1.18 | $-0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $262.2M | — | ||
| Q4 25 | $248.2M | $196.0M | ||
| Q3 25 | $249.4M | $171.0M | ||
| Q2 25 | $235.6M | $150.0M | ||
| Q1 25 | $217.7M | $121.5M | ||
| Q4 24 | $203.7M | $118.8M | ||
| Q3 24 | $205.7M | $104.8M | ||
| Q2 24 | $197.4M | $87.2M |
| Q1 26 | $42.4M | — | ||
| Q4 25 | $39.9M | $-28.6M | ||
| Q3 25 | $33.6M | $-47.2M | ||
| Q2 25 | $36.0M | $-48.0M | ||
| Q1 25 | $31.4M | $-59.4M | ||
| Q4 24 | $102.7M | $-74.9M | ||
| Q3 24 | $33.0M | $-64.6M | ||
| Q2 24 | $29.7M | $-79.3M |
| Q1 26 | 19.4% | — | ||
| Q4 25 | 17.6% | -13.8% | ||
| Q3 25 | 14.1% | -27.0% | ||
| Q2 25 | 17.2% | -24.5% | ||
| Q1 25 | 15.5% | -46.9% | ||
| Q4 24 | 11.3% | -61.1% | ||
| Q3 24 | 20.7% | -59.8% | ||
| Q2 24 | 18.3% | -89.5% |
| Q1 26 | 16.2% | — | ||
| Q4 25 | 16.1% | -14.6% | ||
| Q3 25 | 13.5% | -27.6% | ||
| Q2 25 | 15.3% | -32.0% | ||
| Q1 25 | 14.4% | -48.9% | ||
| Q4 24 | 50.4% | -63.1% | ||
| Q3 24 | 16.0% | -61.7% | ||
| Q2 24 | 15.0% | -91.0% |
| Q1 26 | $1.18 | — | ||
| Q4 25 | $1.10 | $-0.55 | ||
| Q3 25 | $0.93 | $-0.94 | ||
| Q2 25 | $0.99 | $-0.97 | ||
| Q1 25 | $0.86 | $-1.22 | ||
| Q4 24 | $2.79 | $-1.54 | ||
| Q3 24 | $0.90 | $-1.34 | ||
| Q2 24 | $0.81 | $-1.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $147.4M | $322.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $470.2M | $88.3M |
| Total Assets | $580.6M | $689.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $147.4M | — | ||
| Q4 25 | $107.0M | $322.9M | ||
| Q3 25 | $76.1M | $325.3M | ||
| Q2 25 | $73.5M | $303.0M | ||
| Q1 25 | $56.9M | $300.9M | ||
| Q4 24 | $42.5M | $315.4M | ||
| Q3 24 | $62.4M | $327.3M | ||
| Q2 24 | $59.6M | $315.7M |
| Q1 26 | $470.2M | — | ||
| Q4 25 | $542.6M | $88.3M | ||
| Q3 25 | $498.9M | $73.7M | ||
| Q2 25 | $455.6M | $73.1M | ||
| Q1 25 | $462.1M | $53.2M | ||
| Q4 24 | $519.3M | $57.0M | ||
| Q3 24 | $412.8M | $92.9M | ||
| Q2 24 | $371.4M | $102.9M |
| Q1 26 | $580.6M | — | ||
| Q4 25 | $689.0M | $689.8M | ||
| Q3 25 | $640.5M | $669.3M | ||
| Q2 25 | $567.4M | $639.8M | ||
| Q1 25 | $564.7M | $596.7M | ||
| Q4 24 | $626.7M | $568.5M | ||
| Q3 24 | $523.3M | $561.5M | ||
| Q2 24 | $479.3M | $548.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.3M | $-18.7M |
| Free Cash FlowOCF − Capex | — | $-18.7M |
| FCF MarginFCF / Revenue | — | -9.6% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 0.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-93.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.3M | — | ||
| Q4 25 | $65.0M | $-18.7M | ||
| Q3 25 | $86.0M | $1.0M | ||
| Q2 25 | $52.6M | $-32.4M | ||
| Q1 25 | $38.5M | $-43.4M | ||
| Q4 24 | $36.6M | $-26.2M | ||
| Q3 24 | $57.8M | $-18.6M | ||
| Q2 24 | $50.9M | $-30.1M |
| Q1 26 | — | — | ||
| Q4 25 | $63.7M | $-18.7M | ||
| Q3 25 | $84.7M | $988.0K | ||
| Q2 25 | $52.4M | $-32.4M | ||
| Q1 25 | $38.2M | $-43.7M | ||
| Q4 24 | $36.4M | $-26.2M | ||
| Q3 24 | $57.4M | $-18.7M | ||
| Q2 24 | $50.8M | $-30.2M |
| Q1 26 | — | — | ||
| Q4 25 | 25.7% | -9.6% | ||
| Q3 25 | 34.0% | 0.6% | ||
| Q2 25 | 22.2% | -21.6% | ||
| Q1 25 | 17.6% | -36.0% | ||
| Q4 24 | 17.9% | -22.1% | ||
| Q3 24 | 27.9% | -17.9% | ||
| Q2 24 | 25.8% | -34.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 0.0% | ||
| Q3 25 | 0.5% | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q1 25 | 0.1% | 0.3% | ||
| Q4 24 | 0.1% | 0.0% | ||
| Q3 24 | 0.2% | 0.1% | ||
| Q2 24 | 0.0% | 0.1% |
| Q1 26 | 0.81× | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 2.56× | — | ||
| Q2 25 | 1.46× | — | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 0.36× | — | ||
| Q3 24 | 1.75× | — | ||
| Q2 24 | 1.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APPF
| Value Added Services | $201.4M | 77% |
| Subscription Services | $58.2M | 22% |
AXSM
Segment breakdown not available.
